Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Released: January 11, 2021

Expires: January 11, 2022

Program Description

This activity provides an overview of the role of the innate and adaptive immune systems in the development and progression of multiple sclerosis (MS), while exploring the therapeutic implications of immune dysfunction. MS immunotherapies are reviewed, with a focus on their mechanisms of action and immune-related toxicities. Patient case studies are included to illustrate considerations in the selection and sequencing of therapy and the management of immune-related toxicities.

This activity is a recording of a live event that occurred on 12/8/2020.

Intended Audience

This activity has been designed to meet the educational needs of neurologists, nursing professionals, PAs, and other healthcare professionals involved in the management of patients with multiple sclerosis.

Commercial Supporter

This activity is supported by educational grants from Biogen, EMD Serono, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe regulation and dysregulation of the adaptive and the innate immune systems during development and progression of MS
  • Review the mechanisms of action of current and emerging immunotherapies for MS and their relevance to treatment decisions
  • Discuss immune-related toxicities of current and emerging immunotherapies used for MS
  • Utilize strategies to assess and manage immune-related toxicities
  • Evaluate relative risks and benefits of immunotherapeutic options
  • Employ patient-specific considerations when making treatment-sequencing decisions

Provided by The Consortium of Multiple Sclerosis Centers, International Organization of Multiple Sclerosis Nurses, and Catamount Medical Education.

This activity is supported by independent educational grants from Biogen, EMD Serono, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), International Organization of Multiple Sclerosis Nurses (IOMSN), and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA PRA Category 1 Credit(s)TM

The CMSC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Contact Hours

The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (1.0 in the area of pharmacology).

CE for Pharmacists

This knowledge-based activity, UAN JA4008165-9999-21-001-H01-P, qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.

All other healthcare professionals completing this course will be issued a statement of participation.

Activity Staff Disclosures

June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Conflicts of Interest Disclosure Policy

It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance. of evidence-base and fair balance.

Disclosure of Unlabeled Use

CMSC, IOMSN, and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Dr. Lublin may discuss unapproved agents that are in the MS developmental pipeline without any recommendation on their use.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Faculty Disclosures:
Fred D Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai

Dr. Lublin has disclosed the following relationships:
Sources of Funding for Research: Novartis Pharmaceuticals Corp; Teva Neuroscience; Actelion; Transparency Life Sciences; NMSS, Sanofi
Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Biogen; EMD Serono; Novartis; Teva; Actelion; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune; Receptos/Celgene; Forward Pharma; TG Therapeutics; Abbvie; Regeneron; Medday; Atara Biotherapeutics; Polpharma; Mapi Pharma; Innate Immunotherapeutics; Apitope; Orion Biotechnology; Brainstorm Cell Therapeutics


In order to receive CME credits, participants must review the CME/CE information, complete the pre-survey, view the video, complete the post-survey, and program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

For information about the accreditation of this program, please contact [email protected].

Privacy Policy

Catamount Medical Education, LLC, respects your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CNE credit. This information is provided to activity collaborators for the purposes of CME/CNE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

For each visitor to this Web site, our Web server automatically recognizes information such as the visitor’s IP address. We use this information to allow participants to return and begin the activity at the place they last visited. We do not set any cookies on your computer. Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts